HGH Mechanism of Action — Research Reference

Human growth hormone (somatropin, 191-amino-acid recombinant hGH) acts through a single high-affinity receptor on a wide range of tissues. Its physiological effects are split between direct GH receptor signalling and indirect signalling mediated by hepatic IGF-1 secretion.

Receptor Target

GH binds the growth hormone receptor (GHR) — a class I cytokine receptor present on hepatocytes, chondrocytes, adipocytes, skeletal muscle, immune cells, and many other populations. One GH molecule sequentially engages two GHR monomers, inducing receptor dimerization that is the signalling-initiating event.

Signal Transduction

GHR dimerization triggers:

1. JAK2 transphosphorylation — the receptor-associated tyrosine kinase activates and phosphorylates GHR cytoplasmic tyrosines.
2. STAT5 (primarily STAT5b) recruitment and phosphorylation → nuclear translocation → transcription of GH-response genes including IGF-1, ALS, and IGFBP-3.
3. MAPK/ERK — contributes to cell proliferation and differentiation.
4. PI3K/Akt — contributes to insulin-like metabolic effects (glucose uptake, lipid handling).
5. SOCS2 feedback — terminates signalling; defects in this loop produce GH hypersensitivity.

Direct vs IGF-1-Mediated Effects

The published dual-effector model splits GH actions:

• Direct GH effects (independent of IGF-1): lipolysis on adipocytes, insulin antagonism (the diabetogenic effect), and acute amino-acid uptake in muscle.
• IGF-1-mediated effects: skeletal growth (chondrocyte proliferation), most somatic anabolism, and the bulk of long-duration tissue-trophic effects.

Pharmacokinetics

Subcutaneous recombinant hGH peaks at approximately 4–6 hours with a half-life of 2–3 hours; intravenous half-life is approximately 20 minutes. The biological effect substantially outlasts plasma exposure because the downstream IGF-1 generation continues for many hours after a single dose.

Pulsatile vs Continuous Exposure

Native endogenous GH is secreted in discrete pulses (5–6 major nocturnal pulses in adult humans). Continuous exogenous exposure flattens this pattern and is consistently associated with greater tachyphylaxis than pulse-mimicking dosing in published research.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol. 2010;6(9):515–525.
2. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74.
3. Carter-Su C, Schwartz J, Argetsinger LS. Growth hormone signaling pathways. Growth Horm IGF Res. 2016;28:11–15.